Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental
in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are …

Chromosome segregation errors cause aneuploidy and genomic heterogeneity, which are
hallmarks of cancer in humans. A persistent high frequency of these errors (chromosomal …

There remains an unmet need for preclinical models to enable personalized therapy for
ovarian cancer (OC) patients. Here we evaluate the capacity of patient-derived organoids (PDOs…

Anti-EGFR therapy is used to treat metastatic colorectal cancer (CRC) patients, for which
initial response rates of 10–20% have been achieved. Although the presence of HER2 …

Although intracellular signaling and sensitivity to targeted therapies of BRAF fusion genes
are influenced by their 5′ fusion partner, we show that all investigated BRAF fusions confer …

Shallow genome-wide cell-free DNA (cfDNA) sequencing holds great promise for non-invasive
cancer monitoring by providing reliable copy number alteration (CNA) and fragmentomic …

Colorectal cancers (CRCs) with oncogenic mutations in RAS and BRAF are associated with
anti-EGFR therapy resistance. Consequently, all RAS mutant CRC patients are being …

Introduction: In patients with adult-type granulosa cell tumor (aGCT), a rare subtype of ovarian
cancer, surgery is the preferred treatment for both primary and recurrent disease. However…

In vitro generation of platelets from pluripotent stem cells is a promising approach to meet the
demand for therapeutic platelet concentrates. To improve current culture systems, gaining …